title: Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
abstract: 1. In order to develop a predictive model for the preclinical evaluation of anthracycline cardiotoxicity and the means of preventing it, we have studied the functional parameters of perfused hearts isolated from rats receiving repeated doses of several anthracyclines. 2. The anthracyclines studied were doxorubicin, epirubicin, pirarubicin and daunorubicin, and we also studied a liposomal formulation of daunorubicin (DaunoXome) and the co-administration of dexrazoxane (ICRF-187) and doxorubicin. 3. Anthracyclines were administered i.p. at equimolar doses corresponding to 3 mg kg-1 per injection of doxorubicin, every other day for a total of six doses. Dexrazoxane was used at the dose of 30 mg kg-1 per injection and was administered either 30 min before or 30 min after doxorubicin. We evaluated any general toxicity towards the animals as well as alterations of left ventricular contractility and relaxation ex vivo. 4. Epirubicin and daunorubicin were significantly less cardiotoxic than doxorubicin, and neither pirarubicin nor DaunoXome caused significant alterations in cardiac function. There was a direct relationship between the decrease in cardiac contractility or relaxation and anthracycline accumulation in the heart, evaluated after the same treatment schedule. 5. Dexrazoxane induced a significant protection against doxorubicin-induced cardiac toxicity when administered 30 min before doxorubicin, whereas this protection was ineffective when administered 30 min after doxorubicin. Direct perfusion of DaunoXome in isolated hearts of untreated animals resulted in a 12-fold reduction of the accumulation of daunorubicin in heart tissue as compared to the perfusion of free daunorubicin, and did not cause alterations in cardiac function at a dosage for which free daunorubicin induced major alterations. 6. The isolated perfused rat heart appears to be a valuable model for screening of new anthracyclines and of strategies for circumventing anthracycline cardiotoxicity.
authors.affiliation: Department of Medical Biochemistry and Molecular Biology, University of Bordeaux II, France.
authors.forename: P
authors.initials: P
authors.lastname: Pouna
authors.forename: S
authors.initials: S
authors.lastname: Bonoron-Adèle
authors.forename: G
authors.initials: G
authors.lastname: Gouverneur
authors.forename: L
authors.initials: L
authors.lastname: Tariosse
authors.forename: P
authors.initials: P
authors.lastname: Besse
authors.forename: J
authors.initials: J
authors.lastname: Robert
mesh_terms: D000818:Animals; D018943:Anthracyclines / Q000008:administration & dosage / Q000633:toxicity*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000633:toxicity*; D010478:Chemotherapy, Cancer, Regional Perfusion; D003630:Daunorubicin / Q000633:toxicity; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D006331:Heart Diseases / Q000139:chemically induced / Q000517:prevention & control; D066298:In Vitro Techniques; D008081:Liposomes; D008297:Male; D009206:Myocardium / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011929:Razoxane / Q000008:administration & dosage / Q000494:pharmacology; D016277:Ventricular Function, Left / Q000187:drug effects; D017725:Ventricular Pressure / Q000187:drug effects
chemical_list: D018943:Anthracyclines; D008081:Liposomes; D011929:Razoxane; D003630:Daunorubicin